查看文章

Aims: Assess IBD patients starting anti-TNF for the impact of preventive measures in HBV and/or HCV, and the predictive response factors to HBV vaccination.

Methods: Multicenter prospective study including 389 IBD patients. Four interventions were established: I-1) anti-HBs <100 IU/L: HBV vaccination with double doses at 0-1-2 months, and revaccination if titres <100 IU/L (seroprotection defined as anti-HBs10-100 IU/L and effective vaccination anti-HBs >100 IU/L); I-2) anti-HBs >100 IU/L (previous effective vaccination): monitoring levels; I-3) anti-HBc and/or HCV+: analysis every two months; I-4) HBsAg+: start anti-virals.

Results: I-1 and I-2) For first vaccination, effective vaccination and seroprotection were obtained in 26.4% and 43.5%, and for revaccination 31.3% and 44.4%, respectively. Predictive factors of effective vaccination were age ≤ 30 years (OR = 2.2) and being …